Aurobindo Pharma surges as its arm gets USFDA’s final approval for Pemetrexed for Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 528.45, up by 5.30 points or 1.01% from its previous closing of Rs. 523.15 on the BSE.
The scrip opened at Rs. 531.15 and has touched a high and low of Rs. 531.30 and Rs. 518.30 respectively. So far 77248 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1043.00 on 26-May-2021 and a 52 week low of Rs. 514.50 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 514.50 respectively. The current market cap of the company is Rs. 31045.96 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.30% and 9.86% respectively.
Aurobindo Pharma’s wholly owned subsidiary company -- Eugia Pharma Specialties has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pemetrexed for Injection, 100 mg, 500mg and 1000mg. Pemetrexed for Injection USP, 100 mg/vial and 500 mg/vial, Single-Dose Vials, to be bioequivalent and therapeutically equivalent to the RLD, Alimta for Injection, 100 mg/vial and 500 mg/vial of Eli Lilly. The product is being launched immediately. The approved product has an estimated market size of $ 1272 million for the twelve months ending March 2022, according to IQVIA.
This is the 139th ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
